EP3925600A1 — Topical composition comprising calcipotriol and betamethasone dipropionate
Assigned to MC2 Therapeutics Ltd · Expires 2021-12-22 · 4y expired
What this patent protects
The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betameth…
USPTO Abstract
The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, wherein at least one of said discontinuous oil phase(s) comprises medium chain triglycerides and isopropyl myristate, and wherein the isopropyl myristate and medium chain triglycerides are present in a weight ratio of from 3:1 to 12:1.
Drugs covered by this patent
- Diprolene (BETAMETHASONE DIPROPIONATE) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.